Genovis expands Antibody engineering with the launch of two novel products; IgGZero™ and FcDocker™

Genovis introduces two novel products to the market which both facilitates production, purification and modification of antibodies. The products are both more effective and easy to handle than any competing product on the market today. With the two novel products Genovis strengthens and expands the company product portfolio within Antibody Engineering, a rapidly growing market.

The new products are launched today with the premiere show of the animation ‘ IgGZero adventures’ on Genovis website, www.genovis.com.

The target customer for IgGZero™ and FcDOCKER™ are Pharma and Biotech industry focusing on antibody based drug development and the producers of antibody reagents for diagnostic and research applications. Research concerning antibody molecules in drug development increase rapidly and so is the market for effective and high performing research tools and technologies. The total market for Antibody Engineering products is estimated to reach 80 MUSD and the two novel products are examples of products within this particular target market.

-The two novel products are fabulous complementary products to our current product assortment and they add competing value to our customers. We began the development of these products less than one year ago in cooperation with a research group at Lund University. Hence it is even more exiting that we can already now launch these products, says Sarah Fredriksson, CEO at Genovis.

Genovis already holds two unique products within Antibody engineering and with the release of IgGZero™ and FcDOCKER™ this products group is twice as big.

The launched products is to be marketed through out the rest of 2008 with various activities like; advertising, mailing, web activities, customer meetings and seminars and through the distribution network. In addition the two products, the scientific discoveries and data behind them will be presented at the European Antibody Congress 2008 in the beginning of December.

The two novel groups of products launched by Genovis today can be described as tools for efficient down stream processing and modification of antibody molecules.

•IgGZero™ is a unique enzyme which highly specific degrades naturally occurring carbohydrates from the large antibody protein. By removing the carbohydrates the performance of the antibody is significantly enhanced in certain applications such as immunoassaying. Another good example is the removal of antibody molecules from the surface of primary cells using IgGZero™.

•FcDOCKER™ binds with high specificity to the antibody molecule. This protein is accordingly very handy in the production process of antibody molecules. By using FcDOCKER™ the production process is much milder, which in turn enhances the recovery, output and performance in comparison with existing technologies.

About Us

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North

Subscribe

Documents & Links